Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||Cytarabine + Onvansertib||Phase I||Actionable||In a Phase Ib trial, Onvansertib (PCM-075) and low-dose Cytosar-U (cytarabine) combination therapy resulted in an overall response rate of 13% (2/15) in patients with relapsed or refractory acute myeloid leukemia, with 1 patient achieving a complete remission without hematologic recovery, and 25% (3/12) of the evaluable patients achieved a >=50% reduction of bone marrow blasts (PMID: 32998961; NCT03303339).||32998961|